24 results on '"Moravek M"'
Search Results
2. Rhizosphere microbiomes derived from vermicompost alter gene expression and regulatory pathways in tomato (Solanum lycopersicum, L.).
- Author
-
Garcia, J., Moravek, M., Fish, T., Thannhauser, T., Fei, Z., Sparks, J. P., Giovannoni, J., and Kao-Kniffin, J.
- Subjects
- *
TOMATOES , *RHIZOSPHERE microbiology , *GENE expression , *REGULATOR genes , *VERMICOMPOSTING , *RHIZOSPHERE - Abstract
The gut microbiome of worms from composting facilities potentially harbors organisms that are beneficial to plant growth and development. In this experiment, we sought to examine the potential impacts of rhizosphere microbiomes derived from Eisenia fetida worm castings (i.e. vermicompost) on tomato (Solanum lycopersicum, L.) plant growth and physiology. Our experiment consisted of a greenhouse trial lasting 17 weeks total in which tomato plants were grown with one of three inoculant treatments: a microbial inoculant created from vermicompost (V), a microbial inoculant created from sterilized vermicompost (SV), and a no-compost control inoculant (C). We hypothesized that living microbiomes from the vermicompost inoculant treatment would enhance host plant growth and gene expression profiles compared to plants grown in sterile and control treatments. Our data showed that bacterial community composition was significantly altered in tomato rhizospheres, but fungal community composition was highly variable in each treatment. Plant phenotypes that were significantly enhanced in the vermicompost and sterile vermicompost treatments, compared to the control, included aboveground biomass and foliar δ15N nitrogen. RNA sequencing revealed distinct gene expression changes in the vermicompost treatment, including upregulation of nutrient transporter genes such as Solyc06g074995 (high affinity nitrate transporter), which exhibited a 250.2-fold increase in expression in the vermicompost treatment compared to both the sterile vermicompost and control treatments. The plant transcriptome data suggest that rhizosphere microbiomes derived from vermicompost can influence tomato gene expression and growth-related regulatory pathways, which highlights the value of RNA sequencing in uncovering molecular responses in plant microbiome studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Correction to: A synopsis of global frontiers in fertility preservation
- Author
-
Ataman, L. M., Laronda, M. M., Gowett, M., Trotter, K., Anvari, H., Fei, F., Ingram, A., Minette, M., Suebthawinkul, C., Taghvaei, Z., Torres‑Vélez, M., Velez, K., Adiga, S. K., Anazodo, A., Appiah, L., Bourlon, M. T., Daniels, N., Dolmans, M. M., Finlayson, C., Gilchrist, R. B., Gomez‑Lobo, V., Greenblatt, E., Halpern, J. A., Hutt, K., Johnson, E. K., Kawamura, K., Khrouf, M., Kimelman, D., Kristensen, S., Mitchell, R. T., Moravek, M. B., Nahata, L., Orwig, K. E., Pavone, M. E., Pépin, D., Pesce, R., Quinn, G. P., Rosen, M. P., Rowell, E., Smith, K., Venter, C., Whiteside, S., Xiao, S., Zelinski, M., Goldman, K. N., Woodruff, T. K., and Duncan, F. E.
- Published
- 2022
- Full Text
- View/download PDF
4. EFFECT OF PRIOR TRAINING ON REPRODUCTIVE ENDOCRINOLOGIST AND INFERTILITY SPECIALISTS’ KNOWLEDGE, SKILLS, ATTITUDES AND BEHAVIORS REGARDING THE CARE OF TRANSGENDER AND GENDER DIVERSE INDIVIDUALS
- Author
-
Lipkin P, Monseur B, Mayo JA, Moravek M, Nahata L, Amato P, Alvero R, and Obedin-Maliver J
- Subjects
Reproductive Medicine ,Obstetrics and Gynecology - Published
- 2022
5. A synopsis of global frontiers in fertility preservation.
- Author
-
UCL - SSS/IREC/GYNE - Pôle de Gynécologie, UCL - (SLuc) Service de gynécologie et d'andrologie, Ataman, L M, Laronda, M M, Gowett, M, Trotter, K, Anvari, H, Fei, F, Ingram, A, Minette, M, Suebthawinkul, C, Taghvaei, Z, Torres-Vélez, M, Velez, K, Adiga, S K, Anazodo, A, Appiah, L, Bourlon, M T, Daniels, N, Dolmans, Marie-Madeleine, Finlayson, C, Gilchrist, R B, Gomez-Lobo, V, Greenblatt, E, Halpern, J A, Hutt, K, Johnson, E K, Kawamura, K, Khrouf, M, Kimelman, D, Kristensen, S, Mitchell, R T, Moravek, M B, Nahata, L, Orwig, K E, Pavone, M E, Pépin, D, Pesce, R, Quinn, G P, Rosen, M P, Rowell, E, Smith, K, Venter, C, Whiteside, S, Xiao, S, Zelinski, M, Goldman, K N, Woodruff, T K, Duncan, F E, UCL - SSS/IREC/GYNE - Pôle de Gynécologie, UCL - (SLuc) Service de gynécologie et d'andrologie, Ataman, L M, Laronda, M M, Gowett, M, Trotter, K, Anvari, H, Fei, F, Ingram, A, Minette, M, Suebthawinkul, C, Taghvaei, Z, Torres-Vélez, M, Velez, K, Adiga, S K, Anazodo, A, Appiah, L, Bourlon, M T, Daniels, N, Dolmans, Marie-Madeleine, Finlayson, C, Gilchrist, R B, Gomez-Lobo, V, Greenblatt, E, Halpern, J A, Hutt, K, Johnson, E K, Kawamura, K, Khrouf, M, Kimelman, D, Kristensen, S, Mitchell, R T, Moravek, M B, Nahata, L, Orwig, K E, Pavone, M E, Pépin, D, Pesce, R, Quinn, G P, Rosen, M P, Rowell, E, Smith, K, Venter, C, Whiteside, S, Xiao, S, Zelinski, M, Goldman, K N, Woodruff, T K, and Duncan, F E
- Abstract
Since 2007, the Oncofertility Consortium Annual Conference has brought together a diverse network of individuals from a wide range of backgrounds and professional levels to disseminate emerging basic and clinical research findings in fertility preservation. This network also developed enduring educational materials to accelerate the pace and quality of field-wide scientific communication. Between 2007 and 2019, the Oncofertility Consortium Annual Conference was held as an in-person event in Chicago, IL. The conference attracted approximately 250 attendees each year representing 20 countries around the world. In 2020, however, the COVID-19 pandemic disrupted this paradigm and precluded an in-person meeting. Nevertheless, there remained an undeniable demand for the oncofertility community to convene. To maintain the momentum of the field, the Oncofertility Consortium hosted a day-long virtual meeting on March 5, 2021, with the theme of "Oncofertility Around the Globe" to highlight the diversity of clinical care and translational research that is ongoing around the world in this discipline. This virtual meeting was hosted using the vFairs ® conference platform and allowed over 700 people to participate, many of whom were first-time conference attendees. The agenda featured concurrent sessions from presenters in six continents which provided attendees a complete overview of the field and furthered our mission to create a global community of oncofertility practice. This paper provides a synopsis of talks delivered at this event and highlights the new advances and frontiers in the fields of oncofertility and fertility preservation around the globe from clinical practice and patient-centered efforts to translational research.
- Published
- 2022
6. A View from the past into our collective future: the oncofertility consortium vision statement
- Author
-
Woodruff, TK, Ataman-Millhouse, L, Acharya, KS, Almeida-Santos, T, Anazodo, A, Anderson, RA, Appiah, L, Bader, J, Becktell, K, Brannigan, RE, Breech, L, Bourlon, MT, Bumbuliene, Z, Burns, K, Campo-Engelstein, L, Campos, JR, Centola, GM, Chehin, MB, Chen, D, De Vos, M, Duncan, FE, El-Damen, A, Fair, D, Famuyiwa, Y, Fechner, PY, Fontoura, P, Frias, O, Gerkowicz, SA, Ginsberg, J, Gracia, CR, Goldman, K, Gomez-Lobo, V, Hazelrigg, B, Hsieh, MH, Hoyos, LR, Hoyos-Martinez, A, Jach, R, Jassem, J, Javed, M, Jayasinghe, Y, Jeelani, R, Jeruss, JS, Kaul-Mahajan, N, Keim-Malpass, J, Ketterl, TG, Khrouf, M, Kimelman, D, Kusuhara, A, Kutteh, WH, Laronda, MM, Lee, JR, Lehmann, V, Letourneau, JM, McGinnis, LK, McMahon, E, Meacham, LR, Mijangos, MFV, Moravek, M, Nahata, L, Ogweno, GM, Orwig, KE, Pavone, ME, Peccatori, FA, Pesce, RI, Pulaski, H, Quinn, G, Quintana, R, Quintana, T, de Carvalho, BR, Ramsey-Goldman, R, Reinecke, J, Reis, FM, Rios, J, Rhoton-Vlasak, AS, Rodriguez-Wallberg, KA, Roeca, C, Rotz, SJ, Rowell, E, Salama, M, Saraf, AJ, Scarella, A, Schafer-Kalkhoff, T, Schmidt, D, Senapati, S, Shah, D, Shikanov, A, Shnorhavorian, M, Skiles, JL, Smith, JF, Smith, K, Sobral, F, Stimpert, K, Su, HI, Sugimoto, K, Suzuki, N, Thakur, M, Victorson, D, Viale, L, Vitek, W, Wallace, WH, Wartella, EA, Westphal, LM, Whiteside, S, Wilcox, LH, Wyns, C, Xiao, S, Xu, J, Zelinski, M, Woodruff, TK, Ataman-Millhouse, L, Acharya, KS, Almeida-Santos, T, Anazodo, A, Anderson, RA, Appiah, L, Bader, J, Becktell, K, Brannigan, RE, Breech, L, Bourlon, MT, Bumbuliene, Z, Burns, K, Campo-Engelstein, L, Campos, JR, Centola, GM, Chehin, MB, Chen, D, De Vos, M, Duncan, FE, El-Damen, A, Fair, D, Famuyiwa, Y, Fechner, PY, Fontoura, P, Frias, O, Gerkowicz, SA, Ginsberg, J, Gracia, CR, Goldman, K, Gomez-Lobo, V, Hazelrigg, B, Hsieh, MH, Hoyos, LR, Hoyos-Martinez, A, Jach, R, Jassem, J, Javed, M, Jayasinghe, Y, Jeelani, R, Jeruss, JS, Kaul-Mahajan, N, Keim-Malpass, J, Ketterl, TG, Khrouf, M, Kimelman, D, Kusuhara, A, Kutteh, WH, Laronda, MM, Lee, JR, Lehmann, V, Letourneau, JM, McGinnis, LK, McMahon, E, Meacham, LR, Mijangos, MFV, Moravek, M, Nahata, L, Ogweno, GM, Orwig, KE, Pavone, ME, Peccatori, FA, Pesce, RI, Pulaski, H, Quinn, G, Quintana, R, Quintana, T, de Carvalho, BR, Ramsey-Goldman, R, Reinecke, J, Reis, FM, Rios, J, Rhoton-Vlasak, AS, Rodriguez-Wallberg, KA, Roeca, C, Rotz, SJ, Rowell, E, Salama, M, Saraf, AJ, Scarella, A, Schafer-Kalkhoff, T, Schmidt, D, Senapati, S, Shah, D, Shikanov, A, Shnorhavorian, M, Skiles, JL, Smith, JF, Smith, K, Sobral, F, Stimpert, K, Su, HI, Sugimoto, K, Suzuki, N, Thakur, M, Victorson, D, Viale, L, Vitek, W, Wallace, WH, Wartella, EA, Westphal, LM, Whiteside, S, Wilcox, LH, Wyns, C, Xiao, S, Xu, J, and Zelinski, M
- Abstract
PURPOSE: Today, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium. METHODS: The Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process. RESULTS: This interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity. CONCLUSION: The goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future.
- Published
- 2021
7. Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?
- Author
-
Nahata, L, Woodruff, TK, Quinn, GP, Meacham, LR, Chen, D, Appiah, LC, Finlayson, C, Orwig, KE, Laronda, MM, Rowell, EE, Anazodo, A, Frias, O, Rios, JS, Whiteside, S, Gomez-Lobo, V, Dwiggins, M, Childress, KJ, Hoefgen, HR, Levine, JM, Jayasinghe, Y, Moravek, M, Nahata, L, Woodruff, TK, Quinn, GP, Meacham, LR, Chen, D, Appiah, LC, Finlayson, C, Orwig, KE, Laronda, MM, Rowell, EE, Anazodo, A, Frias, O, Rios, JS, Whiteside, S, Gomez-Lobo, V, Dwiggins, M, Childress, KJ, Hoefgen, HR, Levine, JM, Jayasinghe, Y, and Moravek, M
- Published
- 2020
8. A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men
- Author
-
Kinnear, H M, primary, Constance, E S, additional, David, A, additional, Marsh, E E, additional, Padmanabhan, V, additional, Shikanov, A, additional, and Moravek, M B, additional
- Published
- 2019
- Full Text
- View/download PDF
9. T- and H- forms of dc oxygen discharge at medium pressures: spectroscopic study
- Author
-
Schmiedt Lukáš, Morávek Matěj Jan, Kaňka Adolf, and Hrachová Věra
- Subjects
oxygen glow discharge ,t- and h- forms of positive column ,optical emission spectroscopy ,Chemistry ,QD1-999 - Published
- 2014
- Full Text
- View/download PDF
10. Reproductive Health in Trans and Gender Diverse Patients: Effects of transmasculine gender-affirming hormone therapy on future reproductive capacity: clinical data, animal models, and gaps in knowledge.
- Author
-
Chan-Sui R, Kruger RE, Cho E, Padmanabhan V, Moravek M, and Shikanov A
- Subjects
- Animals, Humans, Female, Male, Testosterone therapeutic use, Testosterone pharmacology, Models, Animal, Hormone Replacement Therapy, Reproduction drug effects, Sex Reassignment Procedures methods, Transsexualism drug therapy, Fertility drug effects, Transgender Persons, Reproductive Health
- Abstract
In Brief: Animal studies are needed to inform clinical guidance on the effects of testosterone gender-affirming hormone therapy (T-GAHT) on fertility. This review summarizes current animal models of T-GAHT and identifies gaps in knowledge for future study., Abstract: Testosterone gender affirming hormone therapy (T-GAHT) is frequently used by transgender and gender-diverse individuals assigned female at birth to establish masculinizing characteristics. Although many seek parenthood, particularly as a gestational parent or through surrogacy, the current standard guidance of fertility counseling for individuals on testosterone (T) lacks clarity. At this time, individuals are typically recommended to undergo fertility preservation or stop treatment, associating T-therapy with a loss of fertility; however, there is an absence of consistent information regarding the true fertility potential for transgender and gender-diverse adults and adolescents. This review evaluates recent studies that utilize animal models of T-GAHT to relate to findings from clinical studies, with a more specific focus on fertility. Relevant literature based on murine models in post- and pre-pubertal populations has suggested reversibility of the impacts of T-GAHT, alone or following gonadotropin-releasing hormone agonist (GnRHa), on reproduction. These studies reported changes in clitoral area and ovarian morphology, including corpora lutea, follicle counts, and ovarian weights from T-treated mice. Future studies should aim to determine the impact of the duration of T-treatment and cessation on fertility outcomes, as well as establish animal models that are clinically representative of these outcomes with respect to gender diverse populations.
- Published
- 2024
- Full Text
- View/download PDF
11. Functional Changes to Achilles Tendon and Enthesis in a Mouse Model of an Adolescent Masculine Gender-Affirming Hormone Treatment.
- Author
-
Hold LA, Phillips T, Cordts P, Steltzer S, Bae SH, Henry B, Migotsky N, Grossman S, Cruz CD, Padmanabhan V, Moravek M, Shikanov A, Abraham AC, and Killian ML
- Abstract
Many transgender youth seek gender affirming care, such as puberty suppression, to prolong decision-making and to align their physical sex characteristics with their gender identity. During peripubertal growth, connective tissues such as tendon rapidly adapt to applied mechanical loads (e.g., exercise) yet if and how tendon adaptation is influenced by sex and gender affirming hormone therapy during growth remains unknown. The goal of this study was to understand the how pubertal suppression influences the structural and functional properties of the Achilles tendon using an established mouse model of transmasculine gender affirming hormone therapy. C57BL/6N female-born mice were assigned to experimental groups to mimic gender-affirming hormone therapy in human adolescents, and treatment was initiated prior to the onset of puberty (at postnatal day 26, P26). Experimental groups included controls and mice serially treated with gonadotropin release hormone analogue (GnRHa), delayed Testosterone (T), or GnRHa followed by T. We found that puberty suppression using GnRHa, with and without T, improved the overall tendon load capacity in female-born mice. Treatment with T resulted in an increase in the maximum load that tendon can withstand before failure. Additionally, we found that GnRHa, but not T, treatment resulted in a significant increase in cell density at the Achilles enthesis., Competing Interests: DISCLOSURES The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
12. Body image disturbances in adolescent and young adult cancer patients confronting infertility risk and fertility preservation decisions.
- Author
-
Wytiaz V, Jackson Levin N, Tan CY, Stelmak D, Iannarino N, Zhang A, Ellman E, Herrel L, Moravek M, Walling E, Chugh R, and Zebrack B
- Subjects
- Humans, Young Adult, Adolescent, Body Image, Fear, Fertility Preservation psychology, Neoplasms therapy, Neoplasms psychology, Infertility psychology
- Abstract
Purpose: Body image is a major psychosocial concern for all cancer patients but can affect the adolescent and young adult (AYA) population in distinct ways. Similarly, the prospect of infertility and the fertility preservation process can create additional stress during cancer treatment. Discussions regarding infertility inherently implicate the body and its reproductive function, but downstream effects on self-perception have not been previously described. The aim of this study was to explore the experiences of AYAs as they considered their risk of infertility and options for fertility preservation (FP), specifically the ways in which this impacted body image and FP decision-making., Methods: AYA cancer patients ( n = 27) aged 12-25 years whose cancer and treatment conferred risk of infertility were recruited through electronic health record query at an NCI-Designated Comprehensive Cancer Center. Participants completed semi-structured interviews, which were recorded, transcribed, and deductively coded for themes related to information needs, knowledge of treatment effects on fertility, and reproductive concerns after cancer. Emergent, inductive themes related to body image were identified., Results: Body image concerns, related to both physical appearance and body functioning emerged. Common concerns included anticipating change as it pertains to the body and its functions, physical discomfort, fear of judgment, and meeting expectations of the body. While these themes are broad in nature, they have been previously explored in relation to body image in general and their emergence in the oncofertility space provides guidance for further optimization of infertility and fertility preservation discussions., Conclusions: AYA cancer patients experience a multitude of body image related disturbances when faced with the possibility of infertility and fertility preservation. In identifying and exploring these themes, future opportunities for improving oncofertility practice and discussions among AYAs with a focus on body image positivity are called upon.
- Published
- 2024
- Full Text
- View/download PDF
13. Reproductive late effects after hematopoietic stem cell transplant in pediatric, adolescent, and young adult cancer survivors.
- Author
-
Appiah LC, Moravek M, Hoefgen H, Rotz S, Childress K, Samis J, Benoit J, Rodriguez-Wallberg K, and Anazodo A
- Subjects
- Female, Humans, Child, Adolescent, Young Adult, Quality of Life, Transplantation, Homologous adverse effects, Hematopoietic Stem Cell Transplantation adverse effects, Cancer Survivors, Uterine Cervical Neoplasms
- Abstract
Reproductive late effects after hematopoietic stem cell transplant can have a significant impact on cancer survivors' quality of life. Potential late effects include gonadal insufficiency, genital graft-versus-host disease, uterine injury, psychosexual dysfunction, and an increased risk of breast and cervical cancer in patients treated with total body irradiation. Despite guidelines, screening and treatment are not standardized among at-risk patients. Provider barriers include lack of knowledge of at-risk therapies and evidenced-based guidelines. Patient barriers include a reluctance to report symptoms and lack of awareness of treatment options. System barriers include inefficient implementation of screening tools and poor dissemination of guidelines to providers who serve as the medical home for survivors. This review guides the clinician in identifying and managing reproductive late effects after hematopoietic stem cell transplant to improve outcomes., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
14. Reproductive endocrinologist and infertility specialists' knowledge, skills, behaviors, and attitudes regarding the care for transgender and gender-diverse individuals.
- Author
-
Lipkin P, Monseur B, Mayo J, Moravek M, Nahata L, Amato P, Alvero R, and Obedin-Maliver J
- Abstract
Objective: To investigate associations between reproductive endocrinology and infertility (REI) providers' prior training and current knowledge, skills, attitudes, and behaviors regarding fertility preservation and family building for transgender and gender-diverse (T/GD) patients., Design: The survey was distributed to members of the Society for Reproductive Endocrinology and Infertility, the REI-physician-focused professional body within the American Society for Reproductive Medicine, with additional participants recruited through snowball sampling., Results: Participants (n = 206) reported on training in T/GD care; 51% endorsed prior training. Most participants (93%) believed T/GD individuals were as fit for parenthood as cisgender individuals. Prior training was associated with an increased likelihood of offering T/GD health resources and more frequent consultations with specialist colleagues.Common barriers to providing care indicated by respondents included cost, delays in gender-affirming care, and lack of knowledge of the potential impact of hormonal interventions. Common facilitators included education and training, prior experience, and affordability of services., Conclusions: Most REI providers believed T/GD individuals are fit for parenthood and agreed that prior training facilitates care for T/GD patients. The lack of provider knowledge emerged as a barrier to care. Although training helped facilitate some components of care, systemic barriers such as the cost and variability of patient population characteristics/experiences are important considerations when serving T/GD individuals., (© 2023 Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
15. Pediatric oncofertility care in limited versus optimum resource settings: results from 39 surveyed centers in Repro-Can-OPEN Study Part I & II.
- Author
-
Salama M, Nahata L, Jayasinghe Y, Gomez-Lobo V, Laronda MM, Moravek MB, Meacham LR, Christianson MS, Lambertini M, Anazodo A, Quinn GP, and Woodruff TK
- Subjects
- Male, Female, Humans, Cryopreservation, Surveys and Questionnaires, Australia, Fertility Preservation methods, Neoplasms complications, Neoplasms therapy
- Abstract
Purpose: As a secondary report to elucidate the diverse spectrum of oncofertility practices for childhood cancer around the globe, we present and discuss the comparisons of oncofertility practices for childhood cancer in limited versus optimum resource settings based on data collected in the Repro-Can-OPEN Study Part I & II., Methods: We surveyed 39 oncofertility centers including 14 in limited resource settings from Africa, Asia, and Latin America (Repro-Can-OPEN Study Part I), and 25 in optimum resource settings from the USA, Europe, Australia, and Japan (Repro-Can-OPEN Study Part II). Survey questions covered the availability of fertility preservation and restoration options offered in case of childhood cancer as well as their degree of utilization., Results: In the Repro-Can-OPEN Study Part I & II, responses for childhood cancer and calculated oncofertility scores showed the following characteristics: (1) higher oncofertility scores in optimum resource settings than in limited resource settings for ovarian and testicular tissue cryopreservation; (2) frequent utilization of gonadal shielding, fractionation of anticancer therapy, oophoropexy, and GnRH analogs; (3) promising utilization of oocyte in vitro maturation (IVM); and (4) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, in vitro spermatogenesis, and stem cells reproductive technology as they are still in preclinical or early clinical research settings., Conclusions: Based on Repro-Can-OPEN Study Part I & II, we presented a plausible oncofertility best practice model to help optimize care for children with cancer in various resource settings. Special ethical concerns should be considered when offering advanced and innovative oncofertility options to children., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
16. Soluble and EV-Associated Diagnostic and Prognostic Biomarkers in Knee Osteoarthritis Pathology and Detection.
- Author
-
Moravek M, Matejova J, and Spakova T
- Abstract
Osteoarthritis (OA) is the most common degenerative disease of the connective tissue of the human musculoskeletal system. Despite its widespread prevalence, there are many limitations in its diagnosis and treatment. OA diagnosis currently relies on the presence of clinical symptoms, sometimes accompanied by changes in joint X-rays or MRIs. Biomarkers help not only to diagnose early disease progression but also to understand the process of OA in many ways. In this article, we briefly summarize information on articular joints and joint tissues, the pathogenesis of OA and review the literature about biomarkers in the field of OA, specifically inflammatory cytokines/chemokines, proteins, miRNA, and metabolic biomarkers found in the blood, synovial fluid and in extracellular vesicles.
- Published
- 2023
- Full Text
- View/download PDF
17. Extranodal extension, an international survey on its evaluation and reporting in breast cancer patients.
- Author
-
Tang P, Moravek M, Oprea-Ilies G, Mon KS, and Pambuccian SE
- Subjects
- Humans, Female, Extranodal Extension, Lymphatic Metastasis diagnosis, Lymphatic Metastasis pathology, Lymph Nodes pathology, Prognosis, Keratins, Retrospective Studies, Breast Neoplasms diagnosis, Breast Neoplasms pathology
- Abstract
Lymph node metastasis is the most important prognostic factor for breast cancer patients. In addition to the number of nodes involved and the largest metastatic focus, extranodal extension (ENE) is also used to subclassify breast cancer patients into different risk groups. More recently, pathologists are required to report the size/extent of ENE per the new CAP guideline, as it seems to be associated with more axillary nodal burden and/or a worse prognosis. Although the definition of ENE is largely understood and agreed upon among pathologists around the world, evaluation and reporting for the size of ENE are not. To understand current practice, we conducted an international survey among pathologists who are interested in breast pathology. A total of 70 pathologists responded. The results showed that (1) 98% of the participants reported the presence or absence of ENE and 61% also reported the size of ENE in millimeter (mm). (2) There was no uniform method of measuring the size of ENE; 47% measured the largest dimension regardless of orientation, while 30% measured the largest perpendicular distance from the capsule. (3) The most common factors affecting the accuracy in diagnosis of ENE are the presence of lymphovascular invasion (LVI), lack of capsule integrity, and the presence of fatty hilar or fatty replacement of a lymph node. (4) 71% felt that the H&E stain is adequate to evaluate ENE, deeper levels and IHC analysis for vascular and cytokeratin markers can be helpful if needed. (5) 75% agreed that there is an urgent need to standardize the measurement and reporting for ENE. Our survey highlights the variation in ENE evaluation and the need for its standardization in breast cancer patients with axillary node metastasis., Competing Interests: Competing Interest All authors have no competing interests in regarding this manuscript., (Copyright © 2022 Elsevier GmbH. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
18. "Queer Insights": Considerations and Challenges for Assessing Sex, Gender Identity, and Sexual Orientation in Oncofertility Research.
- Author
-
Levin NJ, Zhang A, Kattari S, Moravek M, and Zebrack B
- Abstract
This article addresses issues related to clinical and research approaches to oncofertility for adolescent and young adult (AYA) sexual and gender minority (SGM) cancer patients. Limited attention has been dedicated to understanding the extent to which oncofertility services are appropriately and equitably delivered to AYAs with diverse orientations toward sexual orientation, gender identity, and future family. Unresolved challenges to conducting research with this vulnerable population perpetuate a lack of adequate knowledge about SGM AYA oncofertility needs. Therefore, the purpose of this paper is to inform considerations of sex, gender identity, and sexual orientation for investigations that include SGM AYAs. In order to improve the knowledge base and clinical services for this population, we discuss (1) challenges to sampling this population; (2) categorization and survey logic (e.g., skip patterns) in light of fluid sexual orientation and gender identities; and (3) clinical implications of accurately assessing sex and gender for oncofertility research and practice. We also recommend strategies for producing inclusive and accurate assessments of sexual and gender identity categories in both research and clinical encounters with SGM AYAs. Incorporating "queer insights" into empirical research - that is, positioning queer theory at the center of oncofertility study design - is suggested as a future direction for oncofertility research and practice.
- Published
- 2022
- Full Text
- View/download PDF
19. Mesenchymal Stem Cells in the Treatment of Human Spinal Cord Injury: The Effect on Individual Values of pNF-H, GFAP, S100 Proteins and Selected Growth Factors, Cytokines and Chemokines.
- Author
-
Slovinska L, Harvanova D, Janockova J, Matejova J, Cibur P, Moravek M, Spakova T, and Rosocha J
- Abstract
At present, there is no effective way to treat the consequences of spinal cord injury (SCI). SCI leads to the death of neural and glial cells and widespread neuroinflammation with persisting for several weeks after the injury. Mesenchymal stem cells (MSCs) therapy is one of the most promising approaches in the treatment of this injury. The aim of this study was to characterize the expression profile of multiple cytokines, chemokines, growth factors, and so-called neuromarkers in the serum of an SCI patient treated with autologous bone marrow-derived MSCs (BM-MSCs). SCI resulted in a significant increase in the levels of neuromarkers and proteins involved in the inflammatory process. BM-MSCs administration resulted in significant changes in the levels of neuromarkers (S100, GFAP, and pNF-H) as well as changes in the expression of proteins and growth factors involved in the inflammatory response following SCI in the serum of a patient with traumatic SCI. Our preliminary results encouraged that BM-MSCs with their neuroprotective and immunomodulatory effects could affect the repair process after injury.
- Published
- 2022
- Full Text
- View/download PDF
20. Small Extracellular Vesicles Derived from Human Chorionic MSCs as Modern Perspective towards Cell-Free Therapy.
- Author
-
Janockova J, Matejova J, Moravek M, Homolova L, Slovinska L, Nagyova A, Rak D, Sedlak M, Harvanova D, Spakova T, and Rosocha J
- Subjects
- Cell Communication, Cell- and Tissue-Based Therapy, Cells, Cultured, Chorion metabolism, Fibroblasts cytology, Fibroblasts metabolism, Humans, Mesenchymal Stem Cells metabolism, Osteoblasts cytology, Osteoblasts metabolism, Chorion cytology, Extracellular Vesicles metabolism, Mesenchymal Stem Cells cytology
- Abstract
Mesenchymal stem cells (MSCs) are of great interest to scientists due to their application in cell therapy of many diseases, as well as regenerative medicine and tissue engineering. Recently, there has been growing evidence surrounding the research based on extracellular vesicles (EVs), especially small EVs (sEVs)/exosomes derived from MSCs. EVs/exosomes can be secreted by almost all cell types and various types of EVs show multiple functions. In addition, MSCs-derived exosomes have similar characteristics and biological activities to MSCs and their therapeutic applications are considered as a safe strategy in cell-free therapy. The aim of this study was the characterization of MSCs isolated from the chorion (CHo-MSCs) of human full-term placenta, as well as the isolation and analysis of small EVs obtained from these cells. Accordingly, in this study, the ability of small EVs' uptake is indicated by synovial fibroblasts, osteoblasts and periosteum-derived MSCs. Improvement in the understanding of the structure, characteristics, mechanism of action and potential application of MSCs-derived small EVs can provide new insight into improved therapeutic strategies.
- Published
- 2021
- Full Text
- View/download PDF
21. Mouse oocyte vitrification with and without dimethyl sulfoxide: influence on cryo-survival, development, and maternal imprinted gene expression.
- Author
-
Cantatore C, George JS, Depalo R, D'Amato G, Moravek M, and Smith GD
- Subjects
- Animals, Blastocyst cytology, Blastocyst drug effects, Blastocyst metabolism, Cryoprotective Agents pharmacology, Female, Gene Expression Profiling, In Vitro Oocyte Maturation Techniques, Mice, Oocytes drug effects, Oocytes metabolism, Parthenogenesis, Prospective Studies, Cryopreservation methods, Dimethyl Sulfoxide pharmacology, Embryonic Development, Gene Expression Regulation, Developmental, Genomic Imprinting, Oocytes growth & development, Vitrification drug effects
- Abstract
Purpose: Oocytes and embryos can be vitrified with and without dimethyl sulfoxide (DMSO). Objectives were to compare no vitrification (No-Vitr), vitrification with DMSO (Vitr + DMSO), and vitrification without DMSO (Vitr - DMSO) on fresh/warmed oocyte survival, induced parthenogenetic activation, parthenogenetic embryo development, and embryonic maternal imprinted gene expression., Methods: In this prospective controlled laboratory study, mature B6C3F1 female mouse metaphase II oocytes were treated as: i) No-Vitr, ii) Vitr + DMSO/warmed, and iii) Vitr - DMSO/warmed with subsequent parthenogenetic activation and culture to the blastocyst stage. Oocyte cryo-survival, parthenogenetic activation and embryo development, parthenogenetic embryo maternal imprinted gene expression were outcome measures., Results: Oocyte cryo-survival was significantly improved in Vitr + DMSO versus Vitr - DMSO at initial warming and 2 h after warming. Induced parthenogenetic activation was similar between all three intervention groups. While early preimplantation parthenogenetic embryo development was similar between control, Vitr + DMSO, Vitr - DMSO oocytes, the development to blastocysts was significantly inferior in the Vitr - DMSO oocytes group compared to the control and Vitr + DMSO oocyte groups. Finally, maternal imprinted gene expression was similar between intervention groups at both the 2-cell and blastocyst parthenogenetic embryo stage., Conclusion(s): Inclusion of DMSO in oocyte vitrification solutions improved cryo-survival and developmental potential of parthenogenetic embryos to the blastocyst stage without significantly altering maternal imprinted gene expression., (© 2021. Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
22. A View from the past into our collective future: the oncofertility consortium vision statement.
- Author
-
Woodruff TK, Ataman-Millhouse L, Acharya KS, Almeida-Santos T, Anazodo A, Anderson RA, Appiah L, Bader J, Becktell K, Brannigan RE, Breech L, Bourlon MT, Bumbuliene Ž, Burns K, Campo-Engelstein L, Campos JR, Centola GM, Chehin MB, Chen D, De Vos M, Duncan FE, El-Damen A, Fair D, Famuyiwa Y, Fechner PY, Fontoura P, Frias O, Gerkowicz SA, Ginsberg J, Gracia CR, Goldman K, Gomez-Lobo V, Hazelrigg B, Hsieh MH, Hoyos LR, Hoyos-Martinez A, Jach R, Jassem J, Javed M, Jayasinghe Y, Jeelani R, Jeruss JS, Kaul-Mahajan N, Keim-Malpass J, Ketterl TG, Khrouf M, Kimelman D, Kusuhara A, Kutteh WH, Laronda MM, Lee JR, Lehmann V, Letourneau JM, McGinnis LK, McMahon E, Meacham LR, Mijangos MFV, Moravek M, Nahata L, Ogweno GM, Orwig KE, Pavone ME, Peccatori FA, Pesce RI, Pulaski H, Quinn G, Quintana R, Quintana T, de Carvalho BR, Ramsey-Goldman R, Reinecke J, Reis FM, Rios J, Rhoton-Vlasak AS, Rodriguez-Wallberg KA, Roeca C, Rotz SJ, Rowell E, Salama M, Saraf AJ, Scarella A, Schafer-Kalkhoff T, Schmidt D, Senapati S, Shah D, Shikanov A, Shnorhavorian M, Skiles JL, Smith JF, Smith K, Sobral F, Stimpert K, Su HI, Sugimoto K, Suzuki N, Thakur M, Victorson D, Viale L, Vitek W, Wallace WH, Wartella EA, Westphal LM, Whiteside S, Wilcox LH, Wyns C, Xiao S, Xu J, and Zelinski M
- Subjects
- Female, Fertility Preservation legislation & jurisprudence, Humans, Male, Neoplasms pathology, Neoplasms therapy, Quality of Life, Cancer Survivors, Fertility physiology, Fertility Preservation trends, Neoplasms epidemiology
- Abstract
Purpose: Today, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium., Methods: The Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process., Results: This interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity., Conclusion: The goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future.
- Published
- 2021
- Full Text
- View/download PDF
23. 2019 Pediatric Initiative Network: Progress, Proceedings, and Plans.
- Author
-
Nahata L, Gomez-Lobo V, Meacham L, Appiah L, Childress K, Hoefgen H, Dwiggins M, Whiteside S, Bjornard K, Rios J, Anazodo A, Finlayson C, Frias O, Woodruff T, and Moravek M
- Subjects
- Adolescent, Adult, Child, Humans, Young Adult, Pediatrics, Sexual Health, Fertility, Neoplasms therapy
- Abstract
Impairment of fertility and sexual/reproductive health are common after oncologic therapy, and are known to have negative impacts on romantic relationships and psychosocial well-being among childhood cancer survivors. The Pediatric Initiative Network (PIN) is an international, multidisciplinary group of providers within the Oncofertility Consortium dedicated to preserving and protecting the fertility of children and adolescents at risk for infertility due to medical conditions or treatments. The PIN and its Best Practices and Research committees meet virtually throughout the year, with one annual in-person meeting. The purpose of this "proceedings" is to highlight key discussion points from the annual PIN meeting which took place on November 11, 2019, to 1) provide a context for pediatric groups across the country on what oncofertility programs are currently doing and why, and 2) inform stakeholders of past, present and future initiatives that may be of value to them and the patient populations they serve.
- Published
- 2020
- Full Text
- View/download PDF
24. Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?
- Author
-
Nahata L, Woodruff TK, Quinn GP, Meacham LR, Chen D, Appiah LC, Finlayson C, Orwig KE, Laronda MM, Rowell EE, Anazodo A, Frias O, Rios JS, Whiteside S, Gomez-Lobo V, Dwiggins M, Childress KJ, Hoefgen HR, Levine JM, Jayasinghe Y, and Moravek M
- Subjects
- Child, Cryopreservation methods, Female, Fertility Preservation methods, Humans, Infertility, Female chemically induced, Infertility, Female pathology, Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cryopreservation standards, Fertility Preservation standards, Infertility, Female prevention & control, Neoplasms drug therapy, Ovary, Standard of Care standards, Tissue and Organ Harvesting methods
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.